«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《中华肺部疾病杂志》[ISSN:1006-6977/CN:61-1281/TN]

卷:

期数:

2024年01期

页码:

19-24

栏目:

论著

出版日期:

2024-02-20

文章信息/Info

Title:

Analysis of diagnostic efficacy of TSPOT.TB, Genechip, AFB, and their combined applications in tuberculosis

作者:

熊欢庆¹; 王惠琴²; 李玉娟³; 刘 刚³; 金发光³

712046 咸阳,陕西中医药大学¹712099 咸阳,陕西中医药大学第二附属医院²710038 西安,空军军医大学唐都医院呼吸与危重症医学科³

Author(s):

Xiong huanqing¹;  Wang huiqin²;  Li yujuan³;  Liu gang³;  Jin Faguang³.

¹Shanxi University of Chinese Medicine, Xianyang 712046, China; ²The Second Affiliated Hospital of Shanxi University of Chinese Medicine, Xianyang 712099, China; ³Department of Respiratory and Critical Care Medicine, The Second Affiliated Hospital of Air Force Medical University, Xi'an 710038, China

关键词:

结核病;  结核感染T细胞斑点实验;  基因芯片;  抗酸杆菌涂片镜检

Keywords:

Tuberculosis;  T cells spot test of tuberculosis infection;  Genechip;  Acid-fast bacilli smear microscopy

分类号:

R562

DOI:

10.3877/cma.j.issn.1674-6902.2024.01.004

摘要:

目的 结核感染T细胞斑点实验(T cells spot test of tuberculosis infection, TSPOT.TB)与基因芯片(Genechip)是一种新型结核诊断检测方法,自2021年1月唐都医院开始常规应用TSPOT.TB、Genechip,评价诊断、分析联合诊断的可行性。方法 回顾性选取2021年1月至2023年4月我院收治的256例住院患者,行T-SPOT.TB、Genechip、抗酸杆菌涂片镜检(acid-fast bacilli smear microscopy, AFB),根据复合参考标准(compostie reference standard, CRS)考虑活动性结核病例。对三种检验方法进行比较和评价。结果 256例患者同时接受T-SPOT.TB、Genechip法、AFB法检测,其中105例(41.02%)确诊为活动性结核病。>60岁141例(55.08%),<60岁115例(44.92%)。>60岁患者,T-SPOT.TB法、AFB法、Genechip法检测结核的敏感性、特异性、AUC分别为:47.45%、82.93%、0.652; 16.94%、98.78%、0.579; 74.57%、98.78%、0.867; <60岁患者,分别为:44.65%、85.50%、0.656; 10.86%、100.00%、0.554; 73.91%、98.55%、0.862。联合检测中,>60岁患者,AFB+Genechip法检验价值最高,敏感性、特异性、AUC为84.74%、97.56%、0.912。<60岁患者,T-SPOT.TB+AFB+Genechip联合诊断价值最高,敏感性、特异性、AUC分别为:100.00%、84.05%、0.920。结论 Genechip检测具有高敏感性与高特异性,在结核病诊断中具有应用价值。TSPOT.TB、AFB、Genechip联合用于结核病的诊断率高,具有临床意义。

Abstract:

Objective The T cells spot test of tuberculosis infection(TSPOT.TB)and Genechip assays are new methods for the diagnosis and detection of tuberculosis(TB)infection. There is limited research on these methods in China. Since January 2021, the TSPOT.TB and Genechip assays have been routinely used at Tangdu Hospital. Therefore, the aim of this study was to investigate the efficacy of TSPOT.TB and Genechip assays and explore the feasibility of their combined diagnosis, providing reference and guidance for TB detection and diagnosis in non-TB comprehensive hospitals. Methods A retrospective study was conducted on 256 hospitalized patients admitted to Tangdu Hospital from January, 2021, to April, 2023. All patients underwent TSPOT.TB, Genechip, and acid-fast bacilli smear microscopy(AFB)tests. Active TB cases were considered based on a composite reference standard(CRS). The three diagnostic methods were compared and evaluated. Results A total of 256 patients underwent TSPOT.TB, Genechip, and AFB testing simultaneously. Among them, 105(41.02%)were diagnosed with active TB. with 141(55.08%)being over 60 years old and 105(44.92%)being under 60 years old. For patients over 60 years old, the sensitivity, specificity, and AUC of T-SPOT.TB, AFB, and Genechip assays for TB detection were as follows: 47.45%, 82.93%, 0.652; 16.94%, 98.78%, 0.579; 74.57%, 98.78%, 0.867. For patients under 60 years old, the sensitivity, specificity, and AUC of T-SPOT.TB, AFB, and Genechip assays for TB detection were as follows: 44.65%, 85.50%, 0.656; 10.86%, 100.00%, 0.554; 73.91%, 98.55%, 0.862. In combined testing, for patients over 60 years old, the AFB+Genechip assay showed the highest diagnostic efficacy with sensitivity, specificity, and AUC of 84.74%, 97.56%,and 0.912, respectively. For patients under 60 years old, the T-SPOT.TB+AFB+Genechip combination had the highest diagnostic efficacy with sensitivity, specificity, and AUC of 100.00%, 84.05%, and 0.920, respectively. Conclusion The Genechip assay has high sensitivity and specificity and is highly valuable in TB diagnosis. However, the combined use of TSPOT.TB, AFB, and Genechip assays for TB diagnosis shows higher efficacy and can more effectively diagnose TB.

参考文献/References:

1 任成山, 林 辉, 杨仕明. 结核病的流行特征与耐多药的窘迫及其策略[J/CD]. 中华肺部疾病杂志(电子版), 2019, 12(3): 269-274.
2 Suarez I, Funger SM, Kroger S, et al. The diagnosis and treatment of tuberculosis[J]. Dtsch Arztebl Int, 2019, 116(43): 729-735.
3 Bagcchi S. WHO's Global Tuberculosis Report 2022[J]. The Lancet Microbe, 2023, 4(1): e20.
4 Maclean E, Kohli M, Weber SF, et al. Advances in molecular diagnosis of tuberculosis[J]. J Clin Microbiol, 2020, 58(10): e01582.
5 Bahr NC, Nuwagira E, Evans EE, et al. Diagnostic accuracy of Xpert MTB/RIF Ultra for tuberculous meningitis in HIV-infected adults: a prospective cohort study[J]. Lancet Infect Dis, 2018, 18(1): 68-75.
6 Ho J, Nguyen P, Nguyen TA, et al. Reassessment of the positive predictive value and specificity of Xpert MTB/RIF: a diagnostic accuracy study in the context of community-wide screening for tuberculosis[J]. Lancet Infect Dis, 2016, 16(9): 1045-1051.
7 Liebenberg D, Gordhan BG, Kana BD. Drug resistant tuberculosis: Implications for transmission, diagnosis, and disease management[J]. Front Cell Infect Microbiol, 2022, 12: 943545.
8 Hamada Y, Cirillo DM, Matteelli A, et al. Tests for tuberculosis infection: landscape analysis[J]. Eur Respir J, 2021, 58(5): 2100167.
9 Whitworth HS, Badhan A, Boakye AA, et al. Clinical utility of existing and second-generation interferon-gamma release assays for diagnostic evaluation of tuberculosis: an observational cohort study[J]. Lancet Infect Dis, 2019, 19(2): 193-202.
10 Pang Y, Li Q, Ou X, et al. Cost-effectiveness comparison of Genechip and conventional drug susceptibility test for detecting multidrug-resistant tuberculosis in China[J]. PLoS One, 2013, 8(7): e69267.
11 Naranbhai V. The role of host genetics(and Genomics)in tuberculosis [J]. Microbiol Spectr, 2016, 4(5). DOI:10.1128/microbiolspec.
12 Clinical and Laboratory Standards Institute(CLSI). Laboratory detection and identification of mycobacteria; approved guideline, CLSI document M48-A.Wayne: CLSI; 2008.[S].
13 Diagnostic Standards and Classification of Tuberculosis in Adults and Children. This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Disease Society of America, September 1999[J]. Am J Respir Crit Care Med, 2000, 161(4 Pt 1):1376-1395.
14 National Health and Family Planning Commission of the People's Republic of China. Diagnosis for pulmonary tuberculosis(WS 288-2017). 2017; Available: http://www.nhc.gov.cn/ewebeditor/uploadfile/2017/11/2017112 8164254246. Accessed 26 May 2018[S].
15 World Health Organization handbook on tuberculosis: module 3:diagnosis: tests for tuberculosis infection. Available: https://www.who.int/publications/i/item/9789240058347. Accessed 30 September 2022[S].
16 李文文, 冯喜英, 关 巍. 结核病诊断与治疗的研究进展[J/CD]. 中华肺部疾病杂志(电子版), 2016, 9(2): 204-206.
17 WHO. Latent tuberculosis infection: updated and consolidated guidelines for programmatic management.2018.https://www.who.int/tb/publications/2018/latent-tuberculosis-infection/en/(accessed March 11, 2019)[S].
18 Lalvani A, Pareek M. Interferon gamma release assays: principles and practice[J]. Enferm Infecc Microbiol Clin, 2010, 28(4): 245-252.
19 Pai M, Denkinger C, Kik S, et al. Gamma interferon release assays for detection of M tuberculosis infection[J]. Clinical Microbiol Rev, 2014, 27: 3-20.
20 Diel R, Loddenkemper R, Nienhaus A. Evidence-based comparison of commercial interferon-gamma release assays for detecting active TB: a metaanalysis[J]. Chest, 2010, 137(4): 952-968.
21 Pai M, Denkinger CM, Kik SV, et al. Gamma interferon release assays for detection of Mycobacterium tuberculosis infection[J]. Clin Microbiol Rev, 2014, 27(1): 3-20.
22 Pan L, Jia H, Liu F, et al. Risk factors for false-negative T-SPOT.TB assay results in patients with pulmonary and extra-pulmonary TB[J]. J Infect, 2015, 70(4): 367-380.
23 Miorner H, Gebre N, Karlsson U, et al. Diagnosis of pulmonary tuberculosis[J]. Lancet, 1994, 344(8915): 127.
24 Vilcheze C, Kremer L. Acid-Fast Positive and Acid-Fast Negative Mycobacterium tuberculosis: The Koch Paradox[J]. Microbiol Spectr, 2017, 5(2).DOI:10.1128/microbiolspec.
25 Lawn SD, Nicol MP. Xpert(R)MTB/RIF assay: development, evaluation and implementation of a new rapid molecular diagnostic for tuberculosis and rifampicin resistance[J]. Future Microbiol, 2011, 6(9): 1067-1082.
26 Toulza F, Tsang L, Ottenhoff TH, et al. Mycobacterium tuberculosis-specific CD4+ T-cell response is increased, and Treg cells decreased, in anthelmintic-treated patients with latent TB[J]. Eur J Immunol, 2016, 46(3): 752-761.
27 Rangaka MX, Wilkinson KA, Glynn JR, et al. Predictive value of interferon-gamma release assays for incident active tuberculosis: a systematic review and meta-analysis[J]. Lancet Infect Dis, 2012, 12(1): 45-55.

备注/Memo

备注/Memo:

通信作者:金发光, Email: jinfag@fmmu.edu.cn

常用功能

更新日期/Last Update: 2024-02-20